Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Current Deferred Revenue (2018 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Current Deferred Revenue for 14 consecutive years, with $111000.0 as the latest value for Q2 2025.

  • Quarterly Current Deferred Revenue fell 90.72% to $111000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $111000.0 through Jun 2025, down 90.72% year-over-year, with the annual reading at $1.3 million for FY2024, 4.58% up from the prior year.
  • Current Deferred Revenue hit $111000.0 in Q2 2025 for Ligand Pharmaceuticals, up from $101000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $25.1 million in Q1 2021 to a low of $101000.0 in Q1 2025.
  • Historically, Current Deferred Revenue has averaged $5.8 million across 5 years, with a median of $1.2 million in 2023.
  • Biggest YoY gain for Current Deferred Revenue was 476.64% in 2021; the steepest drop was 97.78% in 2021.
  • Year by year, Current Deferred Revenue stood at $654000.0 in 2021, then plummeted by 45.72% to $355000.0 in 2022, then skyrocketed by 244.23% to $1.2 million in 2023, then rose by 4.58% to $1.3 million in 2024, then tumbled by 91.31% to $111000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for LGNDZ at $111000.0 in Q2 2025, $101000.0 in Q1 2025, and $1.3 million in Q4 2024.